Sign In
Buy DGNOF
$0.158
-0.0041 (-2.54%)
At Close: Jun 03, 2026
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
11:10am, Thursday, 29'th Feb 2024
BROSSARD, Quebec, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the
DIAGNOS Announces Closing of First Tranche of Private Placement
04:13pm, Tuesday, 27'th Feb 2024
BROSSARD, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues thro
Diagnos Announces Variation in One Insider Ownership of Common Shares
03:50pm, Friday, 23'rd Feb 2024
BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces t
DIAGNOS recognized as a Top TSX Venture Exchange Company
09:00am, Wednesday, 21'st Feb 2024
BROSSARD, Quebec, Feb. 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues thro
DIAGNOS Appoints New Chief Operating Officer
10:00am, Tuesday, 16'th Jan 2024
BROSSARD, Quebec, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
09:15am, Monday, 11'th Dec 2023
BROSSARD, Quebec, Dec. 11, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its
DIAGNOS Announces Closing of Private Placement
05:00pm, Monday, 04'th Dec 2023
BROSSARD, Québec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critic
DIAGNOS AI Retina Analysis is being deployed across Canada's Largest Specialist Care Provider in Diabetes & Endocrinology
11:08am, Thursday, 05'th Oct 2023
BROSSARD, Quebec, Oct. 05, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critica
DIAGNOS Announces Closing of Private Placement and Exercise
09:58pm, Thursday, 18'th May 2023
BROSSARD, Quebec, May 18, 2023 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critica
